Nofech-Mozes S, Vella ET, Dhesy-Thind S, Hagerty KL, Mangu PB, Temin S, Hanna WM (2012) Systematic Review on Hormone Receptor Testing in Breast Cancer. Appl Immunohistochem Mol Morphol 20(3):214–263. https://doi.org/10.1097/PAI.0b013e318234aa12

Article  CAS  PubMed  Google Scholar 

Polyak K (2011) Heterogeneity in breast cancer. J Clin Investig 121(10):3786–3788. https://doi.org/10.1172/JCI60534

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burstein HJ, Griggs JJ, Prestrud AA, Temin S (2010) American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract 6(5):243–246. https://doi.org/10.1200/JOP.000082

Article  PubMed  PubMed Central  Google Scholar 

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784. https://doi.org/10.1016/S0140-6736(11)60993-8

Article  CAS  Google Scholar 

Schneider R, Barakat A, Pippen J, Osborne C (2011) Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update. Breast Cancer Targ Therapy 3:113–125. https://doi.org/10.2147/BCTT.S22905

Article  CAS  Google Scholar 

Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ (2019) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol Off J Am Soc Clin Oncol 37(5):423–438. https://doi.org/10.1200/JCO.18.01160

Article  CAS  Google Scholar 

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836–1846. https://doi.org/10.1056/NEJMoa1701830

Article  PubMed  PubMed Central  Google Scholar 

Pedersen RN, Esen BÖ, Mellemkjær L, Christiansen P, Ejlertsen B, Lash TL, Nørgaard M, Cronin-Fenton D (2022) The incidence of breast cancer recurrence 10–32 years after primary diagnosis. JNCI J Nat Cancer Insti. https://doi.org/10.1093/jnci/djab202

Article  Google Scholar 

Mamby CC, Love RR, Heaney E (1993) Metastatic breast cancer 39 years after primary treatment. Wis Med J 92(10):567–569

CAS  PubMed  Google Scholar 

Tashima Y, Kawano K (2014) A case of local recurrence developing thirty-nine years after mastectomy for breast cancer. Gan Kagaku Ryoho Cancer Chemother 41(3):357–359

Google Scholar 

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VHM, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou M-F, Inbar M, Peto R (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet 381(9869):805–816. https://doi.org/10.1016/S0140-6736(12)61963-1

Article  CAS  Google Scholar 

Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, Poole CJ, Bates T, Chetiyawardana S, Dewar JA, Fernando IN, Grieve R, Nicoll J, Rayter Z, Robinson A, Salman A, Yarnold J, Bathers S, Marshall A, Lee M (2013) aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. https://doi.org/10.1200/jco.2013.31.18_suppl.5

Article  PubMed  PubMed Central  Google Scholar 

Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375(3):209–219. https://doi.org/10.1056/NEJMoa1604700

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gnant M, Fitzal F, Rinnerthaler G, Steger GG, Greil-Ressler S, Balic M, Heck D, Jakesz R, Thaler J, Egle D, Manfreda D, Bjelic-Radisic V, Wieder U, Singer CF, Melbinger-Zeinitzer E, Haslbauer F, Sevelda P, Trapl H, Wette V, Greil R (2021) Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer. N Engl J Med 385(5):395–405. https://doi.org/10.1056/NEJMoa2104162

Article  CAS  PubMed  Google Scholar 

Mamounas EP, Bandos H, Lembersky BC, Jeong J-H, Geyer CE, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade JL, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N (2019) Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(1):88–99. https://doi.org/10.1016/S1470-2045(18)30621-1

Article  CAS  PubMed  Google Scholar 

Monnier A (2006) Effects of adjuvant aromatase inhibitor therapy on lipid profiles. Expert Rev Anticancer Ther 6(11):1653–1662. https://doi.org/10.1586/14737140.6.11.1653

Article  CAS  PubMed  Google Scholar 

Perez EA, Durling FC, Weilbaecher K (2006) Aromatase Inhibitors and Bone Loss. Oncol (Will Park NY) 20(9):1029–1048

Google Scholar 

Hyder T, Marino CC, Ahmad S, Nasrazadani A, Brufsky AM (2021) Aromatase inhibitor-associated musculoskeletal syndrome: understanding mechanisms and management. Front Endocrinol. https://doi.org/10.3389/fendo.2021.713700

Article  Google Scholar 

Hayes DF (2015) Clinical utility of genetic signatures in selecting adjuvant treatment: risk stratification for early vs. late recurrences. Breast 24:S6–S10. https://doi.org/10.1016/j.breast.2015.07.002

Article  PubMed  Google Scholar 

Ballman KV (2015) Biomarker: predictive or prognostic? J Clin Oncol 33(33):3968–3971. https://doi.org/10.1200/JCO.2015.63.3651

Article  CAS  PubMed  Google Scholar 

Vieira AF, Schmitt F (2018) An update on breast cancer multigene prognostic tests—emergent clinical biomarkers. Front Med 5:248. https://doi.org/10.3389/fmed.2018.00248

Article  Google Scholar 

Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M, Austrian Breast and Colorectal Cancer Study Group (ABCSG) (2013) EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol Off J Eur Soc Med Oncol 24(3):640–647. https://doi.org/10.1093/annonc/mds334

Article  CAS  Google Scholar 

Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, Szymonifka J, Bhan AK, Shepherd LE, Zhang Y, Schnabel CA, Erlander MG, Ingle JN, Porter P, Muss HB, Pritchard KI, Tu D, Rimm DL, Goss PE (2013) Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. JNCI J Nat Cancer Instit 105(14):1036–1042. https://doi.org/10.1093/jnci/djt146

Article  CAS  Google Scholar 

Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, Müller-Holzner E, Singer CF, Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Austrian Breast and Colorectal Cancer Study Group (2014) The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 20(5):1298–1305. https://doi.org/10.1158/1078-0432.CCR-13-1845

Article  CAS  Google Scholar 

Wolmark N, Mamounas EP, Baehner FL, Butler SM, Tang G, Jamshidian F, Sing AP, Shak S, Paik S (2016) Prognostic impact of the combination of recurrence score and quantitative estrogen receptor expression (ESR1) on predicting late distant recurrence risk in estrogen receptor-positive breast cancer after 5 years of tamoxifen: results from NRG oncology/national surgical adjuvant breast and bowel project B-28 and B-14. J Clin Oncol 34(20):2350–2358. https://doi.org/10.1200/JCO.2015.62.6630

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, Henry NL, Jhaveri K, Kalinsky K, Kuderer NM, Litvak A, Mayer EL, Pusztai L, Raab R, Wolff AC, Stearns V (2022) Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. J Clin Oncol 40(16):1816–1837. https://doi.org/10.1200/JCO.22.00069

Article  CAS  PubMed  Google Scholar 

Jerevall P-L, Ma X-J, Li H, Salunga R, Kesty NC, Erlander MG, Sgroi DC, Holmlund B, Skoog L, Fornander T, Nordenskjöld B, Stål O (2011) Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 104(11):1762–1769. https://doi.org/10.1038/bjc.2011.145

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noordhoek I, Treuner K, Putter H, Zhang Y, Wong J, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, van de Velde CJH, Schnabel CA, Liefers G-J (2021) Breast cancer index predicts extended endocrine benefit to individualize selection of patients with HR+ early-stage breast cancer for 10 years of endocrine therapy. Clin Cancer Res 27(1):311–319. https://doi.org/10.1158/1078-0432.CCR-20-2737

Article  CAS  PubMed  Google Scholar 

Bartlett JMS, Sgroi DC, Treuner K, Zhang Y, Ahmed I, Piper T, Salunga R, Brachtel EF, Pirrie SJ, Schnabel CA, Rea DW (2019) Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (ATTom) trial. Ann Oncol 30(11):1776–1783. https://doi.org/10.1093/annonc/mdz289

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bartlett JMS, Sgroi DC, Treuner K, Zhang Y, Piper T, Salunga RC, Ahmed I, Doos L, Thornber S, Taylor KJ, Brachtel EF, Pirrie SJ, Schnabel CA, Rea DW (2022) Breast cancer index is a predictive biomarker of treatment benefit and outcome from extended tamoxifen therapy: final analysis of the trans-aTTom study. Clin Cancer Res Off J Am Assoc Cancer Res 28(9):1871–1880. https://doi.org/10.1158/1078-0432.CCR-21-3385

Article  CAS  Google Scholar 

Yamashita H, Ogiya A, Shien T, Horimoto Y, Masuda N, Inao T, Osako T, Takahashi M, Endo Y, Hosoda M, Ishida N, Horii R, Yamazaki K, Miyoshi Y, Yasojima H, Tomioka N, Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society (2016) Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer 23(6):830–843. https://doi.org/10.1007/s12282-015-0649-0

Article  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J,